Hepatitis D Virus

2017 ◽  
pp. 361-374 ◽  
Author(s):  
Raymundo Paraná ◽  
Maria Isabel Schinoni ◽  
Mauricio de Souza Campos
Keyword(s):  
Hepatitis D ◽  
Hepatitis D Virus

scholarly journals Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease

Gut ◽  
2021 ◽  
pp. gutjnl-2020-323888
Author(s):  
Stephan Urban ◽  
Christoph Neumann-Haefelin ◽  
Pietro Lampertico
Keyword(s):  
Hepatitis B ◽  
Hepatitis B Surface Antigen ◽  
Treatment Strategies ◽  
Phase Iii ◽  
Interferon Α ◽  
T Cell Epitopes ◽  
The European Union ◽  
Hepatitis D ◽  
Hepatitis D Virus

Approximately 5% of individuals infected with hepatitis B virus (HBV) are coinfected with hepatitis D virus (HDV). Chronic HBV/HDV coinfection is associated with an unfavourable outcome, with many patients developing liver cirrhosis, liver failure and eventually hepatocellular carcinoma within 5–10 years. The identification of the HBV/HDV receptor and the development of novel in vitro and animal infection models allowed a more detailed study of the HDV life cycle in recent years, facilitating the development of specific antiviral drugs. The characterisation of HDV-specific CD4+ and CD8+T cell epitopes in untreated and treated patients also permitted a more precise understanding of HDV immunobiology and possibly paves the way for immunotherapeutic strategies to support upcoming specific therapies targeting viral or host factors. Pegylated interferon-α has been used for treating HDV patients for the last 30 years with only limited sustained responses. Here we describe novel treatment options with regard to their mode of action and their clinical effectiveness. Of those, the entry-inhibitor bulevirtide (formerly known as myrcludex B) received conditional marketing authorisation in the European Union (EU) in 2020 (Hepcludex). One additional drug, the prenylation inhibitor lonafarnib, is currently under investigation in phase III clinical trials. Other treatment strategies aim at targeting hepatitis B surface antigen, including the nucleic acid polymer REP2139Ca. These recent advances in HDV virology, immunology and treatment are important steps to make HDV a less difficult-to-treat virus and will be discussed.

Chronic Hepatitis D Virus (HDV) Infection in Hepatitis B Virus Carrier Chimpanzees Experimentally Superinfected with HDV

1988 ◽  
Vol 158 (1) ◽  
pp. 151-159 ◽  
Author(s):  
F. Negro ◽  
K. F. Bergmann ◽  
B. M. Baroudy ◽  
W. C. Satterfield ◽  
H. Popper ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Hepatitis D ◽  
Hepatitis D Virus ◽  
B Virus ◽  
Hepatitis B Virus Carrier ◽  
Hdv Infection ◽  
Virus Carrier

Epidemiology of hepatitis D virus (HDV) infection in an urban area of Northern Italy

Infection ◽  
2012 ◽  
Vol 40 (5) ◽  
pp. 485-491 ◽  
Author(s):  
M. De Paschale ◽  
M. T. Manco ◽  
L. Belvisi ◽  
C. Magnani ◽  
T. Re ◽  
...  
Keyword(s):  
Urban Area ◽  
Northern Italy ◽  
Hepatitis D ◽  
Hepatitis D Virus ◽  
Hdv Infection

Site-Specific Engineering of Chemical Functionalities on the Surface of Live Hepatitis D Virus

2013 ◽  
Vol 52 (52) ◽  
pp. 13970-13974 ◽  
Author(s):  
Shixian Lin ◽  
Huan Yan ◽  
Lin Li ◽  
Maiyun Yang ◽  
Bo Peng ◽  
...  
Keyword(s):  
Hepatitis D ◽  
Site Specific ◽  
Hepatitis D Virus

scholarly journals Hepatitis D Virus Replication

2015 ◽  
Vol 5 (11) ◽  
pp. a021568 ◽  
Author(s):  
John M. Taylor
Keyword(s):  
Virus Replication ◽  
Hepatitis D ◽  
Hepatitis D Virus

scholarly journals Origins and Evolution of Hepatitis B Virus and Hepatitis D Virus

2016 ◽  
Vol 6 (1) ◽  
pp. a021360 ◽  
Author(s):  
Margaret Littlejohn ◽  
Stephen Locarnini ◽  
Lilly Yuen
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Hepatitis D ◽  
Hepatitis D Virus ◽  
B Virus
Sign in / Sign up

Export Citation Format

Share Document